Intarcia Therapeutics Obtains $200,000,000 New Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=2c4017a8-3478-4333-a8e9-271ec212ff3e
Date 4/1/2014
Company Name Intarcia Therapeutics
Mailing Address 155 Seaport Boulevard 11th Floor Boston, MA 02210 USA
Company Description Intarcia Therapeutics Inc, a privately held pharmaceutical company, is developing therapies for the treatment of cancer, immunological, and infectious diseases.
Proceeds Purposes In this latest transaction, Intarcia further retains control of its lead product candidate ITCA 650 – its novel once-yearly GLP-1 for type two diabetes, currently being investigated in a global phase 3 clinical trial program called FREEDOM.